Zealand Pharma AS (LTS:0NZU) Cyclically Adjusted FCF per Share: kr-5.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0NZU Zealand Pharma AS LTS:0NZU
40 GF Score
Price kr337.70
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS Cyclically Adjusted FCF per Share?

Zealand Pharma AS LTS:0NZU +2.64% 40 Cyclically Adjusted FCF per Share is kr-5.74 as of Jun. 2026. GuruFocus rates LTS:0NZU with a GF Score™ of 40/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Zealand Pharma AS's adjusted free cash flow per share for the three months ended in Jun. 2026 was kr5.538. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-5.74 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 27.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Zealand Pharma AS was 27.20% per year. The lowest was -32.60% per year. And the median was -18.10% per year.

As of today (2026-08-14), Zealand Pharma AS's current stock price is kr337.70. Zealand Pharma AS's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was kr-5.74. Zealand Pharma AS's Cyclically Adjusted Price-to-FCF of today is .


Zealand Pharma AS  (LTS:0NZU) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Zealand Pharma AS Cyclically Adjusted FCF per Share Related Terms


Zealand Pharma AS Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Cyclically Adjusted FCF per Share Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.47 -14.08 -14.01 -15.27 -5.35

Zealand Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.73 -4.08 -5.35 -6.63 -5.74

LTS:0NZU vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Cyclically Adjusted Price-to-FCF falls into.


LTS:0NZU
40GF Score
Zealand Pharma AS LTS:0NZU
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma AS's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.538/122.9700*122.9700
=5.538

Current CPI (Jun. 2026) = 122.9700.

Zealand Pharma AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -1.933 100.200 -2.372
201612 4.218 100.300 5.171
201703 -2.053 101.200 -2.495
201706 -4.820 101.200 -5.857
201709 0.013 101.800 0.016
201712 -3.411 101.300 -4.141
201803 -3.043 101.700 -3.679
201806 -3.734 102.300 -4.488
201809 -3.459 102.400 -4.154
201812 -4.926 102.100 -5.933
201903 1.575 102.900 1.882
201906 -4.415 102.900 -5.276
201909 -5.007 102.900 -5.984
201912 -4.850 102.900 -5.796
202003 -5.983 103.300 -7.122
202006 -3.010 103.200 -3.587
202009 -2.853 103.500 -3.390
202012 -6.721 103.400 -7.993
202103 -8.840 104.300 -10.422
202106 -7.568 105.000 -8.863
202109 -4.879 105.800 -5.671
202112 -7.502 106.600 -8.654
202203 -7.427 109.900 -8.310
202206 -5.151 113.600 -5.576
202209 -2.734 116.400 -2.888
202212 -5.467 115.900 -5.800
202303 -3.841 117.300 -4.027
202306 -3.071 116.400 -3.244
202309 -2.030 117.400 -2.126
202312 0.842 116.700 0.887
202403 -3.687 118.400 -3.829
202406 -3.787 118.500 -3.930
202409 -4.187 118.900 -4.330
202412 -2.594 118.900 -2.683
202503 -7.202 120.200 -7.368
202506 118.689 120.700 120.921
202509 -6.364 121.600 -6.436
202512 -15.326 121.200 -15.550
202603 -9.673 121.680 -9.776
202606 5.538 122.970 5.538

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-5.74 mean?
Zealand Pharma AS (LTS:0NZU) has a Cyclically Adjusted FCF per Share of kr-5.74 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Cyclically Adjusted FCF per Share too high?
Zealand Pharma AS's current Cyclically Adjusted FCF per Share is kr-5.74. Overall, Zealand Pharma AS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Zealand Pharma AS's Cyclically Adjusted FCF per Share of kr-5.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Cyclically Adjusted FCF per Share is kr-5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (LTS:0NZU) has a current Cyclically Adjusted FCF per Share of kr-5.74. The current Cyclically Adjusted FCF per Share is kr-5.74. Zealand Pharma AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Zealand Pharma AS (LTS:0NZU), the current Cyclically Adjusted FCF per Share is kr-5.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
40GF Score

Get the complete analysis for LTS:0NZU

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr337.70
Price